# Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes

- Jeroen P Jansen
^{1, 2}Email author and - Shannon Cope
^{1}

**12**:152

https://doi.org/10.1186/1471-2288-12-152

© Jansen and Cope; licensee BioMed Central Ltd. 2012

**Received: **11 April 2012

**Accepted: **20 September 2012

**Published: **8 October 2012

## Abstract

### Background

Recently, network meta-analysis of survival data with a multidimensional treatment effect was introduced. With these models the hazard ratio is not assumed to be constant over time, thereby reducing the possibility of violating transitivity in indirect comparisons. However, bias is still present if there are systematic differences in treatment effect modifiers across comparisons.

### Methods

In this paper we present multidimensional network meta-analysis models for time-to-event data that are extended with covariates to explain heterogeneity and adjust for confounding bias in the synthesis of evidence networks of randomized controlled trials. The impact of a covariate on the treatment effect can be assumed to be treatment specific or constant for all treatments compared.

### Results

An illustrative example analysis is presented for a network of randomized controlled trials evaluating different interventions for advanced melanoma. Incorporating a covariate related to the study date resulted in different estimates for the hazard ratios over time than an analysis without this covariate, indicating the importance of adjusting for changes in contextual factors over time.

### Conclusion

Adding treatment-by-covariate interactions to multidimensional network meta-analysis models for published survival curves can be worthwhile to explain systematic differences across comparisons, thereby reducing inconsistencies and bias. An additional advantage is that heterogeneity in treatment effects can be explored.

## Background

Healthcare decision-making requires comparisons of relevant competing treatments for a particular disease state. In the absence of trials involving a direct comparison of interventions, an indirect comparison can provide useful evidence for the treatment effects between competing interventions [1–6]. Even when direct evidence is available, combining consistent direct and indirect estimates will result in more precise treatment effect estimates [2–6]. In general, if the evidence base consists of multiple randomized controlled trials (RCTs) with each trial having at least one intervention in common with another, this network of RCTs can be synthesized with meta-analysis techniques: a network meta-analysis (or mixed treatment comparison meta-analysis) [1–6].

Traditional (network) meta-analyses for survival outcomes are based on hazard ratios (HR) and rely on the proportional hazards assumption, which is implausible if the hazard functions of competing interventions cross. Ouwens et al. (2011) and Jansen (2011) presented methods for (network) meta-analysis of survival data using a multidimensional treatment effect as an alternative to the synthesis of the constant HRs [7, 8]. The hazard functions of the interventions in a trial are modeled using known parametric survival functions (e.g. Weibull or Gompertz) or fractional polynomials and the difference in the parameters are considered the multidimensional treatment effect, which are synthesized (and indirectly compared) across studies. In essence, with this approach the treatment effects are represented by multiple parameters rather than a single parameter.

For network meta-analysis it is important that transitivity (i.e. the consistency assumption) holds for the treatment effect measure of interest [2, 3, 9]. Violations of the proportional hazards assumption will compromise transitivity and can result in biased indirect and mixed treatment comparisons of survival outcomes [8]. By incorporating additional parameters for the treatment effect as proposed with the methods by Ouwens et al. and Jansen, the proportional hazards assumption is relaxed and indirect comparisons are less likely to be biased [7, 8]. However, violation of the proportional hazards assumption is not the only possible source of bias. Since randomization of patients does not hold across trials, there might be an imbalance in patient or study level covariates across comparisons [4–6, 9]. If these covariates are effect-modifiers of the (time varying) HRs, transitivity will be violated and the network meta-analysis will result in biased estimates, despite modeling a multidimensional treatment effect.

In this paper, the models proposed by Ouwens et al. and Jansen are extended with treatment-by-covariate interactions to adjust for confounding bias due to systematic differences in treatment effect modifiers across comparisons. These models also have the advantage of explaining heterogeneity in the treatment effects. The method is illustrated with an example.

## Methods

### Multidimensional network meta-analysis models for survival data

*d*

_{ BC }) can be obtained from the estimates of the effect of B versus A (

*d*

_{ AB }) and the effect of C versus A (

*d*

_{ AC }):

*d*

_{ BC }

*= d*

_{ AC }

*- d*

_{ AB }; as such, transitivity holds [2, 3, 6]. For an arm-based model with the outcome of treatment

*x*as a function of time,

*f*

_{ x }

*(t)*where x =

*A, B, or C*and

*t*represents time, this consistency assumption translates into:

where *h*
_{
jkt
} reflect the underlying hazard rate in trial *j* for intervention *k* at time point *t*. *μ*
_{
jbt
} are the study *j* specific hazard rates at time *t* with comparator treatment *b*. *δ*
_{
jbk
} reflects the study specific constant log HRs of treatment *k* relative to comparator treatment *b* and are drawn from a normal distribution with the pooled estimates expressed in terms of the overall reference treatment *A: d*
_{
bk
}=*d*
_{
Ak
} − *d*
_{
Ab
} with *d*
_{
AA
} = 0. Variance *σ*
^{2} reflects the heterogeneity across studies. As an alternative to a non-parametric baseline hazard function, the development of the hazard rate over time can be described by parametric functions, such as Weibull or Gompertz.

#### Two-dimensional treatment effects without covariates (Model 1)

where *h*
_{
jkt
} again reflects the underlying hazard rate in trial *j* for intervention *k* at time point *t* and is now described as a function of time *t* with *p*=*{*-2,-1,-0.5,0,0.5,1,2,3*}* and *t*
^{0}=ln(t) with treatment and study specific scale and shape parameters *β*
_{0jk
} and *β*
_{1jk
}. (In the example presented below details on the likelihood and data structure are provided). If *β*
_{1jk
} equals 0, a constant log hazard function is obtained, reflecting exponentially distributed survival times. If *β*
_{1jk
} ≠ 0 and *p* = 1 a linear log hazard function is obtained which corresponds to a Gompertz survival function [8]. If *β*
_{1jk
} ≠ 0 and *p* = 0 a Weibull hazard function is obtained. The vectors $\left(\begin{array}{c}\hfill {\mu}_{0jb}\hfill \\ \hfill {\mu}_{1jb}\hfill \end{array}\right)$ are trial specific and reflect the true underlying scale and shape parameters of the comparator treatment *b*. *δ*
_{0jbk
} is the study specific difference in the scale parameter *β*
_{0} of the log hazard curve for treatment *k* relative to comparator treatment *b. δ*
_{0jbk
} are drawn from a normal distribution with the pooled estimates expressed in terms of the overall reference treatment *A*: *d*
_{0Ak
} − *d*
_{0Ab
} with *d*
_{0AA
} = 0. The parameters *d*
_{0Ak
} correspond to the treatment effect of k relative to overall reference treatment *A* with a proportional hazard model. The pooled difference in the shape parameter *β*
_{1} of the log hazard curve for treatment *k* relative to comparator treatment *b* is expressed as *d*
_{1Ak
} − *d*
_{1Ab
} with *d*
_{1AA
} = 0. *d*
_{1Ak
} reflects the change in the log HR over time. For a proportional hazards model *d*
_{1Ak
} equals 0. By incorporating *d*
_{1Ak
} in addition to *d*
_{0Ak
} a multidimensional treatment effect is used. For additional flexibility, the first order fractional polynomial model can be generalized to a 2^{nd} order fractional polynomial model, representing 3-dimensional treatment effects [8].

Variance *σ*
_{
0
}
^{2} reflects the heterogeneity in the difference in the scale parameters across studies. A random effects model with only a heterogeneity parameter for *d*
_{0Ak
} implies that the between study variance of the log hazard ratios remains constant over time.

#### Two-dimensional treatment effects with treatment specific covariate interactions (Model 2)

Since randomization only holds within a trial, the distribution of covariates may vary across studies for a particular type of comparison, as well as between different types of comparisons. Variation in treatment effect modifiers across studies within comparisons results in heterogeneity and an imbalance in effect modifiers between different types of comparisons results in violations of the consistency assumption. [2–4, 6, 9, 10]. Network meta-analysis models can be extended with treatment-by-covariate interactions in an attempt to adjust for this confounding bias or to explore sources of heterogeneity [9–14].

*k*relative to overall reference treatment

*A*:

*β*
_{
xbk
} reflects the impact of study level covariate *X*
_{
j
} on the difference in the scale parameters of the hazard functions with treatment *k* relative to control treatment *b*. Now *d*
_{0bk
} is the difference in scale treatment k relative to *b* when the covariate value equals zero. *Since β*
_{
xbk
} = *β*
_{
xAk
} − *β*
_{
xAb
} with *β*
_{
xAA
} = 0, *k − 1* different and independent regression coefficients for *β*
_{
xAk
} will be estimated with the model. As an alternative to independent treatment-by-covariate interactions, one can also assume exchangeable interaction effects [10].

#### Two-dimensional treatment effects with constant covariate interaction (Model 3)

*X*

_{ j }on the scale parameter of each treatment

*k*relative to

*A*is the same for all treatments. This assumption can be defended when treatments indirectly compared are all from the same class and there is no (biological) reason to assume that a patient characteristic, or any other contextual aspect of the study, modifies treatment effects differently for the different drugs compared. Furthermore, the assumption of constant treatment-by-covariate interaction can also be useful when evaluating the impact of study (design) characteristics (or bias) on treatment effects. [10, 14]. The corresponding network meta-analysis model will be:

*k*relative to

*A*the impact of the covariate is the same,

*β*

_{ x }

*X*

_{ j }will cancel out for the comparison of treatment

*k*relative to

*b*when

*b ≠*A

*AB*and

*AC*studies according to Models 1–3 assuming the hazard over time follows a Weibull distribution, i.e.

*p = 0*. The

*AB*and

*AC*planes reflect the pooled effect estimates of treatment

*B*and

*C*relative to

*A*as a function of time and a covariate value. The vertical axis represents model parameters

*d*

_{0Ak }with

*k = B, C,*corresponding to the log-HR of treatment

*B*and

*C*relative to

*A*at time

*t*= 0 and covariate value

*X = 0*. The slope of the

*AB*and

*AC*planes as a function of ln(time) represents parameter

*d*

_{1Ak }, the impact of time on the log HR of treatment

*k*relative to

*A*. The slope of the

*AB*and

*AC*planes as a function of the covariate value represents

*β*

_{ xAk }, which is the impact of covariate

*X*on the treatment effect parameter

*d*

_{0Ak }(the scale). Figure 1A represents Model 1 where it is assumed that the covariate is not an effect modifier of

*d*

_{0Ak }and therefore

*β*

_{ xAk }= 0. In Figure 1B the effect of the covariate for the

*AB*comparison is different from the

*AC*comparison (Model 2). Figure 1C reflects Model 3 with the same effect of the covariate for the

*AB*and the

*AC*comparison.

*δ*s that they estimate. Bayesian random effects models with a heterogeneity parameter for

*d*

_{0Ak }can be easily extended to fit trials with 3 or more treatment arms by decomposing a multivariate normal distribution as a series of conditional univariate distributions [9, 13]:

*i*given the previous

*1,….(i-1)*arms are:

#### Higher dimensional models with heterogeneity and covariate effects acting on multiple treatment effect parameters

$\left(\begin{array}{c}\hfill {\beta}_{\mathit{xAk}}^{0}\hfill \\ \hfill {\beta}_{\mathit{xAk}}^{1}\hfill \\ \hfill {\beta}_{\mathit{xAk}}^{2}\hfill \end{array}\right)$ reflect the impact of study level covariate *X*
_{
j
} on the pooled treatment effects in terms of scale, *δ*
_{0jbk
}, and shape *δ*
_{1jbk
} and *δ*
_{2jbk
}, with treatment *k* relative to control treatment *b*.

Σ is the between study covariance matrix with *σ*
_{0}, *σ*
_{1}, *σ*
_{2} representing the heterogeneity in treatments effects *δ*
_{0jbk
}, *δ*
_{1jbk
} and *δ*
_{2jbk
} respectively. *ρ*
_{01}, *ρ*
_{02} and *ρ*
_{12} are the correlations between these parameters. Although such a general model is very flexible to explore heterogeneity and inconsistency, identifiability is expected to be a challenge.

### Illustrative example

An example of the models is presented for a network meta-analysis of treatment of advanced (stage IIIc or IV) melanoma. Although the interventions compared in the network in this example do not reflect the latest treatment options for melanoma, it provides a useful illustration of the survival models with covariates.

*q*consecutive intervals over the follow-up period: [

*t*

_{1},

*t*

_{2}], (

*t*

_{2},

*t*

_{3}], …, (

*t*

_{ q },

*t*

_{ q+1}] with

*t*

_{1}=0. For each time interval

*m*=1,2,3,…,

*.q*extracted survival proportions were used to calculate the patients at risk at the beginning of that interval and incident number of deaths. (A more specific explanation is provided in the Additional file 1 of this paper.) A binomial likelihood distribution of the incident events for every interval can be described according to:

Where *r*
_{
jkt
} is the observed number of events in the m^{th} interval ending at time point *t*
_{
m+1} for treatment *k* in study *j*. *n*
_{
jkt
} is the number of subjects at risk just before the start of that interval adjusted for the subjects censored in the interval. *p*
_{
jkt
} is the corresponding underlying event probability. When the time intervals are relatively short, the hazard rate *h*
_{
jkt
} at time point *t* for treatment *k* in study *j* can be assumed to be constant for any time point within the corresponding m^{th} time interval. The hazard rate corresponding to *p*
_{
jkt
} for the m^{th} interval can be standardized by the unit of time used for the analysis (e.g. months) according to: *h*
_{
jkt
} = − ln(1 − *p*
_{
jkt
})/*Δt*
_{
jkt
} where Δ*t*
_{
jkt
} is the length of the interval. For the model estimation we assign this underlying hazard to time point *t*
_{
m+1}.

Study date can be considered a proxy for potential changes over time in (background) medical care and other contextual factors that influence the treatment effects. For the included RCTs, there is variation within and between different types of comparisons regarding study date. The impact of study date on treatment effects was evaluated with the following meta-regression models: 1) random and fixed effects Weibull (*p = 0*) survival models without treatment-by-covariate interaction (Model 1; Figure 1A); 2) random and fixed effects Weibull survival models with treatment specific covariate interaction terms (Model 2; Figure 1B); 3) random and fixed effects Weibull survival models with a constant treatment-by-covariate interaction (Model 3; Figure 1C). Only Weibull models were used because the ln (−ln(Survival)) versus ln(time) showed linear relations for the different studies, indicating Weibull models are appropriate [25].

With constant covariate interaction, *β*
_{
xAk
} ∼ *normal*(0, 10^{4}) will be replaced with *β*
_{
x
} ∼ *normal*(0, 10^{4}). With the fixed effects model, it is not necessary to define a prior distribution for *σ*
_{0}.

The parameters of the different models were estimated using a Markov Chain Monte Carlo (MCMC) method as implemented in the WinBUGS software package [26]. (See Additional file 1 for the code) The first 80,000 iterations from the WinBUGS sampler were discarded as ‘burn-in’ and the inferences were based on an additional 50,000 iterations using two chains. Convergence of the chains was confirmed by the Gelman-Rubin statistic.

The deviance information criterion (DIC) was used to compare the goodness-of-fit of the different models [27, 28]. DIC provides a measure of model fit that penalizes model complexity according to $DIC=\stackrel{\xc2\xaf}{D}+pD,pD=\stackrel{\xc2\xaf}{D}-\widehat{D}$[28]. $\stackrel{\xc2\xaf}{D}$ is the posterior mean residual deviance [28], *pD* is the ‘effective number of parameters’ and $\widehat{D}$ is the deviance evaluated at the posterior mean of the model parameters. In general, a more complex model will result in a better fit to the data, demonstrating a smaller residual deviance. The model with the lowest DIC is the model providing the ‘best’ fit to the data adjusted for the number of parameters.

## Results

### Illustrative example

**Goodness of fit estimates for fixed effects and random effects network meta-analysis models**

Model | Dbar | Dhat | pD | DIC |
---|---|---|---|---|

Random effects Weibull model without covariates | 1462.4 | 1432.3 | 30.1 | 1492.5 |

Fixed effects Weibull model without covariates | 1468.9 | 1443.0 | 25.9 | 1494.8 |

Models with study data as covariate | ||||

Random effects Weibull model with treatment specific covariate interactions | 1460.5 | 1428.5 | 32.0 | 1492.5 |

Fixed effects Weibull model with treatment specific covariate interactions | 1464.7 | 1436.7 | 28.0 | 1492.7 |

Random effects Weibull model with constant treatment covariate interactions | 1459.7 | 1428.7 | 31.0 | 1490.7 |

Fixed effects Weibull model with constant treatment covariate interactions | 1466.7 | 1439.9 | 26.8 | 1493.5 |

*d*

_{0Ak }). The treatment-by-covariate interaction for non-DTIC vs. DTC (−0.02) was different than the interaction term obtained with a model with a constant interaction term (0.05), which implies that the assumption of a constant covariate interaction can be challenged.

**Model parameters for fixed and random effects two-dimensional (Weibull) network meta-analysis models with and without treatment-by-covariate interaction**

Fixed effects model | Random effects model (model 1) | Random effects model with treatment specific covariate interaction* (model 2) | Random effects model with constant treatment-by-covariate interaction* (model 3) | |||||
---|---|---|---|---|---|---|---|---|

Median of posterior distribution | 95% Credible Interval | Median of posterior distribution | 95% Credible Interval | Median of posterior distribution | 95% Credible Interval | Median of posterior distribution | 95% Credible Interval | |

Pooled estimate for difference in scale | ||||||||

DTIC + IFN vs. DTIC ( | −0.16 | (−0.63; 0.33) | −0.22 | (−0.76; 0.23) | −0.04 | (−0.54; 0.47) | −0.18 | (−0.58; 0.39) |

DTIC + non-IFN vs. DTIC ( | −0.07 | (−0.46; 0.34) | −0.19 | (−0.65; 0.30) | −0.16 | (−0.66; 0.32) | −0.10 | (−0.51; 0.35) |

non-DTIC vs. DTIC ( | −0.27 | (−0.63; 0.13) | −0.30 | (−0.88; 0.24) | −0.17 | (−1.40; 1.11) | −0.43 | (−1.12; 0.06) |

Pooled estimate for difference in shape | ||||||||

DTIC + IFN vs. DTIC ( | 0.13 | (−0.08; 0.33) | 0.14 | (−0.04; 0.34) | 0.12 | (−0.07; 0.30) | 0.16 | (−0.04; 0.30) |

DTIC + non-IFN vs. DTIC ( | −0.06 | (−0.23; 0.11) | −0.02 | (−0.19; 0.15) | −0.04 | (−0.21; 0.13) | −0.05 | (−0.19; 0.10) |

non-DTIC vs. DTIC ( | 0.04 | (−0.17; 0.23) | 0.06 | (−0.15; 0.27) | 0.09 | (−0.11; 0.29) | 0.03 | (−0.16; 0.21) |

Estimate for covariate effect ( | ||||||||

DTIC + IFN vs. DTIC ( | 0.06 | (−0.02; 0.16) | 0.05 | (−0.01; 0.12) | ||||

DTIC + non-IFN vs. DTIC ( | 0.06 | (−0.05; 0.18) | 0.05 | (−0.01; 0.12) | ||||

non-DTIC vs. DTIC ( | −0.02 | (−0.21; 0.19) | 0.05 | (−0.01; 0.12) | ||||

Between study variance (heterogeneity) in scale | 0.21 | (0.02; 0.56) | 0.19 | (0.01; 0.52) | 0.18 | (0.01; 0.55) |

*d*

_{0Ak }, and

*d*

_{1Ak }, with

*k = B,C,D,*corresponding to respectively DTIC + IFN, DTIC + non-IFN and non-DTIC) the resultant HRs as a function of time were obtained according to ln(

*HR*

_{ Ak }) =

*d*

_{0Ak }+

*d*

_{1Ak }· ln(

*t*). Figure 4A reflects the HRs over time (along with 95% credible intervals) with a random effects model without adjustment for differences in study date across studies and comparisons. Figure 4B shows the HR over time after adjustment for differences in study date using a random effect model with treatment specific covariate interactions (model 2). The HRs over time are presented for the average study date of all studies. Figure 4C shows the HRs over time after adjustment for study date using a random effect model with a constant treatment-covariate interaction (model 3). Comparing Figure 4A with Figure 4B and 4c illustrates the effect of ignoring the variation in study date across the different comparisons.

**Difference in expected survival (in months) between interventions as obtained with random effects network meta-analysis model with and without treatment-by-covariate interaction**

Random effects model without covariate interaction (model 1) | Random effects model with treatment specific covariate interaction (model 2) | Random effects model with constant treatment-by-covariate interaction (model 3) | ||||
---|---|---|---|---|---|---|

Median of posterior distribution | 95% Credible Interval | Median of posterior distribution | 95% Credible Interval | Median of posterior distribution | 95% Credible Interval | |

DTIC + IFN vs. DTIC | −1.12 | (−4.20; 3.49) | −2.46 | (−5.72; 1.91) | −1.90 | (−5.10; 2.22) |

DTIC + non-IFN vs. DTIC | 3.63 | (−1.72; 10.75) | 3.77 | (−1.04; 10.72) | 3.21 | (−2.39; 9.65) |

non-DTIC vs. DTIC | 2.66 | (−2.38; 13.49) | 1.16 | (−7.51; 25.76) | 6.60 | (−0.78; 21.39) |

DTIC + non-IFN vs. DTIC + IFN | 4.71 | (−1.38; 11.37) | 6.26 | (0.26; 13.29) | 5.13 | (−1.15; 11.50) |

non-DTIC vs. DTIC + IFN | 3.81 | (−2.40; 14.11) | 3.46 | (−6.00; 27.88) | 8.48 | (−0.65; 24.00) |

non-DTIC vs. DTIC + non-IFN | −0.84 | (−9.15; 10.3) | −2.79 | (−13.90; 22.17) | 3.27 | (−6.72; 20.74) |

## Discussion

In this paper, the network meta-analysis models proposed by Ouwens et al. and Jansen for survival data are extended with treatment-by-covariate interactions to explain heterogeneity and possibly to adjust for confounding bias due to inconsistency [7, 8]. The primary advantage of these evidence synthesis models for survival data is that they do not rely on a proportional hazards assumption across studies and comparisons, and any inconsistency due to imbalance in known and measured treatment effect modifiers can be (partly) adjusted for. Although models to incorporate covariates in network meta-analysis have been presented before, this is the first application where treatment effects act on two separate parameters [10–14].

Since the treatment effect acts on both scale and shape with these network meta-analysis models, differences in treatment effect modifiers across studies can (in principle) cause heterogeneity and inconsistency in terms of both the scale and shape. Accordingly, treatment-by-covariate interactions to explain heterogeneity or minimize inconsistency can be of a multidimensional nature as well. However, identifiability of models with treatment-by-covariate interactions for both scale and shape may be very challenging. Under the assumption that heterogeneity of treatment effects only act on the scale parameter, we need at least 2 studies for at least one of the treatment comparisons in the network to estimate a corresponding random effects model. If also covariate interactions are assumed for this effect, even more studies are needed. If we want to estimate heterogeneity and/or treatment-by-covariate interactions in terms of shape, we run in the additional challenge of decreasing sample size and event counts for longer follow-up time points, thereby making the estimation of any shape related parameter beyond a fixed treatment effect challenging. To ensure model identifiability, it is recommended to use network meta-analysis models with fixed treatment effects in terms of shape and only heterogeneity and treatment-by-covariate interactions regarding treatment effects in terms of the scale. Given the presence of a time related treatment effect in these models (i.e. shape), it is unlikely that study characteristics, patient characteristics, and contextual factors (which are most likely unaffected by time) have an impact on heterogeneity and inconsistency beyond the constant component of the treatment effect (i.e. the scale). More complex models with heterogeneity and covariate interactions in terms scale and shape parameters are only expected to be feasible if a large number of studies with sufficient number of events for longer follow-up times are available.

To estimate treatment specific covariate interaction terms (Model 2) we need sufficient covariate variation across the studies for each intervention *k* relative to an overall anchor treatment (A). For models with a constant covariate interaction term (Model 3) we have fewer parameters to estimate and these models are therefore easier to identify. Furthermore, for these models we do not necessarily need spread in the covariate across studies for each type of comparison relative to A; we only need sufficient variation across studies comparing any intervention relative to treatment A. An alternative approach to estimate treatment specific covariate interaction terms is a model with exchangeable interaction effects described by a normal distribution [10]. Such a model allows interaction estimates that shrink towards a common mean, thereby improving parameter estimation.

This network meta-analysis was based on survival proportions extracted from published Kaplan-Meier curves, used to calculate the incident number of deaths and patients at risk per interval according to an algorithm described by Jansen (See Additional file 1 of this paper) [7, 8]. Guyot et al. recently proposed an improved algorithm to reconstruct the data from published Kaplan-Meier curves, which provides a closer approximation of the censoring times, thereby possibly improving the accuracy in terms of the number of patients at risk and allowing greater accuracy of the uncertainty in model parameter estimates [29].

In the present paper, covariate adjustment was based on study-level or aggregate level data. A challenge with meta-regression models using study level data is that the association between a patient characteristic and the treatment effect of the studied interventions at the study level may not reflect the individual level effect-modification of that covariate [30, 31]. Hence, the models can only be used with study level data when there is between-study or between-comparison variation with limited variation in effect modifiers within studies. This is typically the case for study design characteristics or characteristics of the intervention such as dose. However, in the case of imbalances in baseline patient characteristics across comparisons, variation in these characteristics is often present within studies, in which case patient level data is required to ensure valid adjustment for inconsistency. Furthermore, patient-level data provides a greater opportunity to explore differences in effects among subgroups. However, obtaining patient-level data for all RCTs in the network may be considered unrealistic. If there is only individual patient data available for a subset of trials, combining individual patient data for this subset with study level data from the other studies provides a useful alternative [31].

The proposed models can also be used to adjust for differences in terms of baseline risk or placebo response across the trials. The placebo response reflects the impact of all study or patient characteristics that have an impact on the outcome; the placebo response summarizes the impact of prognostic factors (i.e. the study effect). If there is an association between the placebo response and treatment effects, it implies that some or all of the study and patient characteristics that are prognostic factors of the outcomes are also treatment effect modifiers. Adjustment for the placebo response partly mitigates inconsistency or bias due to an imbalance in effect modifiers across comparisons [9, 10]. This may be important given the challenge of adjusting for multiple differences in effect modifiers using study-level data and the limited feasibility of accessing individual patient data for all trials. A limitation of adjusting for baseline risk in a network meta-analysis is the (theoretical) possibility of introducing collider stratification bias [9].

Although network meta-analysis where the treatment effects contain a time related aspect has obvious advantages in terms of model fit to the data, the presentation of the results might need some familiarization. The advantage of presenting HRs as a function of time (Figure 4) is that time varying treatment effects can be identified, but a possible disadvantage is the challenge to identify whether one treatment is overall favourable over another, especially when the HR curves cross. Pooled treatment specific survival curves as shown in Figure 5 provide information on commonly understood concepts like median survival and survival at different time points. A disadvantage, however is that a baseline survival curve with treatment A needs to be defined in order to translate the HR curves as obtained with the network meta-analysis into (pooled) survival curves by treatment. In the current example the pooled curve with treatment A was based on the average of study specific nuisance parameters for scale and shape of all treatment A (i.e. DTIC) controlled trials.

Within a Bayesian framework it is possible to calculate the probability of being the best treatment out of all those treatments assessed, or second best, third best, etc. [32]. With the time varying treatment effects obtained from the network meta-analysis models presented in this paper there are different options to create probabilistic summaries of treatment effects. We can either present a probabilistic summary based on a collapsed measure of the time varying treatment effects, or present probabilistic summaries as a function of time. Examples of the first category are based on the median survival or expected survival obtained from the pooled survival curves. Probabilistic summaries over time can be based on the HR at each time point, the survival proportion at each time point, or the area under the survival curve (AUC) to the left of each time point. Figure 6 is based on this concept and summarizes the cumulative treatment effect. Additional research is required to understand the sensitivity of these different probabilistic measures to the estimated underlying basic model parameters for the treatment effect, and provide some guidance.

A multidimensional network meta-analysis model for survival data is extremely useful for cost-effectiveness analysis because estimates of expected survival differences of competing interventions are less likely to be biased [7, 8]. The extension of the two-dimensional model to include covariates allows for an evaluation of patient subgroups for which the clinical or cost effectiveness of the technology might be expected to differ from the overall population. Although the current analysis focused on overall survival, this method can be applied to any time to event outcomes. It may be of interest to extend the model to evaluate both progression-free and overall survival simultaneously using a multivariate approach, as has been proposed by Welton et al. [33]. This will avoid any inconsistency between clinical evidence synthesis and economic evaluations based on models with differences in quality of life before and after disease progression.

## Conclusion

Adding treatment-by-covariate interactions to multidimensional network meta-analysis models for published survival curves can be worthwhile to explain systematic differences across studies and to reduce inconsistencies. An additional advantage is that heterogeneity in survival data can be addressed. These models are not only useful for comparative effectiveness evaluation, but also provide an opportunity to ensure consistency within a cost-effectiveness analysis. In the Additional file 1 the data requirements to perform analysis with these kinds of models are outlined.

## Declarations

### Acknowledgements

We like to acknowledge the following colleagues who provided useful feedback while developing the presented models: Mario Ouwens, Felicity Buckley, and Alex Ellis. Furthermore, the suggestions by reviewers helped improve the paper. The research was performed without specific funding.

## Authors’ Affiliations

## References

- Lumley T: Network meta-analysis for indirect treatment comparisons. Stat Med. 2002, 21: 2313-2324. 10.1002/sim.1201.View ArticlePubMedGoogle Scholar
- Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004, 23: 3105-3124. 10.1002/sim.1875.View ArticlePubMedGoogle Scholar
- Caldwell DM, Ades AE, Higgins JPT: Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Br Med J. 2005, 331: 897-900. 10.1136/bmj.331.7521.897.View ArticleGoogle Scholar
- Jansen JP, Fleurence R, Devine B, et al: Interpreting indirect treatment comparisons & NMA for health care decision-making: Report of the ISPOR Task Force on indirect treatment comparisons good research practices—Part 1. Value Health. 2011, 14: 417-428. 10.1016/j.jval.2011.04.002.View ArticlePubMedGoogle Scholar
- Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barret A: Conducting Indirect Treatment Comparison and Network Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices - Part 2. Value Health. 2011, 14: 429-437. 10.1016/j.jval.2011.01.011.View ArticlePubMedGoogle Scholar
- Lu G, Ades AE: Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006, 101: 447-459. 10.1198/016214505000001302.View ArticleGoogle Scholar
- Ouwens M, Philips Z, Jansen JP: Network meta-analysis of parametric survival curves. Research Synthesis Methods. 2011Google Scholar
- Jansen JP: Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011, 11: 61-10.1186/1471-2288-11-61.View ArticlePubMedPubMed CentralGoogle Scholar
- Jansen JP, Schmid CH, Salanti G: Direct Acyclic graphs can help understand bias in indirect and mixed treatment comparisons. J Clin Epidemiology. 2012, 65: 798-807. 10.1016/j.jclinepi.2012.01.002.View ArticleGoogle Scholar
- Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ: Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009, 28: 1861-81. 10.1002/sim.3594.View ArticlePubMedGoogle Scholar
- Nixon RM, Bansback N, Brennan A: Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med. 2007, 26: 1237-1254. 10.1002/sim.2624.View ArticlePubMedGoogle Scholar
- Salanti G, Marinho V, Higgins JPT: A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol. 2009, 62: 857-864. 10.1016/j.jclinepi.2008.10.001.View ArticlePubMedGoogle Scholar
- Salanti G, Dias S, Welton NJ, Ades A, Golfinopoulos V, Kyrgiou M, Mauri D, Ioannidis JPA: Evaluating novel agent effects in multiple-treatments meta-regression. Stat Med. 2010, 29: 2369-2383.PubMedGoogle Scholar
- Dias S, Sutton AJ, Welton NJ, Ades AE: NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-rgression, bias, and bias-adjustment. 2011, http://www.nicedsu.org.uk,Google Scholar
- Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH: Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative oncology Group Study. J Clin Oncology. 1998, 16: 1743-51.Google Scholar
- Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncology. 1991, 9: 1403-8.Google Scholar
- Chiarion SV, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L, et al: Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res. 2001, 11: 189-96. 10.1097/00008390-200104000-00015.View ArticleGoogle Scholar
- Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncology. 2000, 18: 158-66.Google Scholar
- Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New Engl J Med. 1992, 327: 516-23. 10.1056/NEJM199208203270803.View ArticlePubMedGoogle Scholar
- Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncology. 2004, 22: 1118-25. 10.1200/JCO.2004.04.165.View ArticleGoogle Scholar
- Thomson DB, Adena M, McLeod GR, Hersey P, Gill PG, Coates AS, et al: Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res. 1993, 3: 133-8.PubMedGoogle Scholar
- Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, et al: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncology. 1994, 12: 806-11.Google Scholar
- Young AM, Marsden J, Goodman A, Burton A, Dunn JA: Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol). 2001, 13: 458-65.Google Scholar
- Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncology. 1999, 17: 2745-51.Google Scholar
- Latimer N: NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011, http://www.nicedsu.org.uk,Google Scholar
- Spiegelhalter D, Thomas A, Best N, Lunn D: WinBUGS User Manual: Version 1.4. 2003, Cambridge: MRC Biostatistics UnitGoogle Scholar
- Dempster AP: The direct use of likelihood for significance testing. Stat Comput. 1997, 7: 247-252. 10.1023/A:1018598421607.View ArticleGoogle Scholar
- Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A: Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society, Series B. 2002, 64: 583-639. 10.1111/1467-9868.00353.View ArticleGoogle Scholar
- Guyot P, Ades AE, Ouwens MJNM, Welton NJ: Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012, 12: 9-10.1186/1471-2288-12-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Schmid CH, Stark PC, Berlin JA, Landais P, Lau J: Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol. 2004, 57: 683-97. 10.1016/j.jclinepi.2003.12.001.View ArticlePubMedGoogle Scholar
- Jansen JP: Network meta-analysis of individual and aggregate level data. Research Synthesis Methods. 2012, 3: 177-190. 10.1002/jrsm.1048.View ArticlePubMedGoogle Scholar
- Salanti G, Ades AE, Ioannidis JP: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011, 64: 163-71. 10.1016/j.jclinepi.2010.03.016.View ArticlePubMedGoogle Scholar
- Welton NJ, Willis SR, Ades AE: Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies. Research Synthesis Methods. 2010, 1: 239-257. 10.1002/jrsm.21.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2288/12/152/prepub

### Pre-publication history

## Copyright

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.